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Abstract 
 
Background: Diffuse Midline Glioma, formerly Diffuse Intrinsic Pontine Glioma (DIPG), is the 
deadliest pediatric brainstem tumor with median survival of less than one year. Here, we investigated 
1) whether direct delivery of adenovirus expressing CD40L (Ad-CD40L) to brainstem tumors would 
induce immune-mediated tumor clearance and, 2) if so, whether therapy would be associated with a 
manageable toxicity due to immune-mediated inflammation in the brainstem. 
Methods: Syngeneic gliomas in the brainstems of immune competent mice were treated with Ad-
CD40L and survival, toxicity and immune profiles determined. A clinically translatable vector, whose 
replication would be tightly restricted to tumor cells, rAd-Δβ4-CD40L, was tested in human patient-
derived Diffuse Midline Gliomas and immunocompetent models.  
Results: Expression of Ad-CD40L restricted to brainstem gliomas by pre-infection induced complete 
rejection, associated with immune cell infiltration, of which CD4+ T cells were critical for therapy. 
Direct intra-tumoral injection of Ad-CD40L into established brainstem tuors improved survival and 
induced some complete cures but with some acute toxicity. RNA-seq analysis showed that Ad-CD40L 
therapy induced neuroinflammatory immune responses associated with IL-6, IL-1  and TNF-α. 
Therefore, to generate a vector whose replication, and transgene expression, would be tightly 
restricted to tumor cells, we constructed rAd-Δβ4-CD40L, the backbone of which has already entered 
clinical trials for Diffuse Midline Glioma.  Direct intra-tumoral injection of rAd-Δβ4-CD40L, with 
systemic blockade of IL-6 and IL-1 , generated significant numbers of cures with readily manageable 
toxicity.   
Conclusions: Virus-mediated delivery of CD40L has the potential to be effective in treating Diffuse 
Midline Gliomas without obligatory neuroinflammation-associated toxicity. 
 
Key words: adenovirus, CD40L, immunotherapy, brainstem tumors, tertiary lymphoid structure 
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Key points:  
 Ad-CD40L therapy improves survival through induction of immune cell infiltration 
 CD4 T cells are important in Ad-CD40L therapy 
 
Importance of the Study: 
New, aggressive therapies for pediatric brainstem tumors including Diffuse Midline Gliomas are 
urgently required. CD40/CD40L engagement has generated potent anti-tumor responses in anatomc
locations where high levels of inflammation are acceptable. Our study here is the f rs  to investigate 
whether such CD40L-induced inflammation in brainstem tumors can be tolerated. We demonstrate 
here that, when CD40L expression was tightly restricted to tumor cells, Ad-CD40L significantly 
prolonged survival of brainstem tumor-bearing mice. Depletion of CD4 T cells abolished Ad-CD40L 
therapy, and decreased levels of antigen-presenting cells. A replication competent adenovirus 
engineered to replicate only in tumor cells (rAd-Δβ4-CD40L) had cytopathic effects on patient-
derived Diffuse Midline Glioma cells and improved survival of mice bearing brainstem tumors in 
vivo. Our results show that it is possible to develop a novel, potentially highly effective 
immunotherapy for Diffuse Midline Glioma, without unacceptable toxicity, which can be translated 
into clinical trials. 
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Introduction   
Brainstem gliomas represent about 10-15% of pediatric central nervous system tumors1.  Of 
these Diffuse Midline Glioma (formerly Diffuse Intrinsic Pontine Glioma (DIPG) ) is the major cause 
of death, with survival rates of fewer than 9 months from diagnosis1. Focal radiation to the pons 
remains the main therapy for newly diagnosed disease and the addition of chemotherapy, targeted 
therapies, differentiation agents, and radiation sensitizers has not significantly impacted outcomes. 
Moreover, surgery is not an option due to the critical location within the brain2. Therefore, new 
therapeutic modalities are urgently needed.  
Cancer immunotherapy has dramatically improved treatment of several tumors with immune 
checkpoint inhibitors and chimeric antigen receptor (CAR) T cell therapies, although not appreciably 
so far in children with brain tumors3. Oncolytic virotherapy utilizes engineered viruses which 
preferentially replicate in tumor cells, leading to cell death and stimulation of the immune system and 
has been clinically investigated in brain tumors4. Immunotherapies for tumors in the brainstem pose 
unique potential dangers associated with inflammation in this location.  However, e have shown that 
diverse immunotherapies can extend survival in mice bearing brainstem tumors without catastrophic 
neurological toxicity5, opening the path for testing novel immunotherapies for this disease. 
CD40 ligand (CD40L:CD154) is expressed both as a membrane-bound form on activated 
helper T cells and as a soluble form by platelets6. CD40/CD40L engagement develops T helper 
dependent immune responses, provides proliferation/differentiation signals to B cells, and triggers 
maturation of antigen-presenting cells (APC) for induction of cytotoxic T lymphocytes7.  Therefore, 
agonistic antibodies against CD40, and viral vectors expressing CD40L, have been successfully t sted 
against several malignancies, including glioblastoma8, and are associated with priming cytotoxic 
CD8+ T cells, reducing regulatory T cells, and activating tumor-associated macrophages9.  
In models of subcutaneous melanoma, where local inflammation was well tolerated, we 
demonstrated that CD40L expressed from a replication-defective adenoviral vector (Ad-CD40L) 
significantly enhanced survival and primed anti-tumor CD8+ T cells10,11. Others have shown that Ad-
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CD40L activates dendritic cells, increases the intra-tumoral Teffector/Tregulatory cell ratio
12, and combines 
with checkpoint inhibitors to eradicate tumors13.  Therefore, we investigated whether Ad-CD40L 
could be an effective treatment for brainstem tumors, whilst simultaneously monitoring whether the 
inflammation associated with anti-tumor therapy could be controlled/tolerated. Using 
immunocompetent models to assess the efficacy/toxicity balance of adenovirus expressing CD40L, 
we show here that tumor-restricted expression of CD40L represents a novel, potentially highly 
effective immunotherapy for Diffuse Midline Glioma with an acceptable toxicity profile. 
Materials and methods (Additional detailed methods are provided in the supplementary 
section).   
Cell lines  
GL261, CT2A, 293A cell lines were grown in DMEM (HyClone) supplemented with 10% FBS (Life 
Technologies).  Mixed astrocytes were cultured in DMEM (HyClone) supplemented with 10% FBS 
(Life Technologies), 1% penicillin/streptomycin (Corning) and 1% sodium pyruvate (Sigma). 
SJPDGF1 and SF7761 Diffuse Midline Glioma neurospheres were cultured in TSM media. 
Viruses 
Ad-GFP or Ad-CD40L serotype 5 replication defective adenoviruses express the green fluorescent 
protein (GFP) or murine CD40L under the CMV promoter in E1, respectively11. rAd-Δβ4-luc or rAd-
Δβ4-CD40L are replication competent adenoviruses expressing luciferase or murine CD40L in which 
24-bp of E1A was deleted14-16.  
In vivo studies 
All studies were approved by the Mayo Foundation Institutional Animal Care and Use Committee. 
Female C57BL/6 mice (6-8 mice/group) were challenged (2µl) with tumor cells or virus a 
stereotactic implantation using established coordinates in the frontal lobe or brainstem17.  
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Flow Cytometry 
Brain-infiltrating leucocytes (BILs) were harvested in RPMI from perfused brains. BILs were 
prepared using dounce homogenization and Percoll gradient18. Immune cells were analyzed using 
FlowJo 10.  
Histology and immunofluorescence 
Brains were fixed in 10% formalin and hematoxylin and eosin was stained by Mayo Clinic Histology 
Core Facility. Immunofluorescence staining was as described19.  
RNA-seq analysis of gene expression 
10d established GL261 tumor-bearing mice were intra-tumorally injected (2µl) with PBS or 5×106 pfu 
Ad-GFP or Ad-CD40L. On day 8, brains were dissected for RNA extraction (RNeasy, Qiagen). RNA 
samples were then subjected to RNA-seq analysis at the Genome Analysis Core, Mayo Clinic. 
Tumor-specific IgG detection 
Sera were harvested on day 8 post-virus injection and used as primary antibody. 1×105 GL261 cells, 
or mixed astrocytes, were stained (1:10 dilution) at 4 °C for 30 min, and 1:100 of Alexa Fluor®488 
goat anti-mouse IgG (H+L) antibody (Invitrogen) were added for flow analysis.  
 
Viability assays 
GL261 cells were plated at 1×104 cells for overnight. 24 hours later, GL261, SJPDGF1, or SF7761 
cells (1×105) were infected with viruses at different MOIs. At indicated time points, cell viability was 
assessed by alamarBlue Cell™ Viability Reagent (ThermoFisher Scientific). 
For CD4+ T cell co-culture assays, GL261 cells were seeded in 96 well plates in triplica e and treated 
with CD4+T cells at an Effector:Target ratio of 10:1.  48hrs later, wells were washed gently 3x in PBS 
to remove non-adherent cells.  Surviving cells were trypsinized, resuspended in PBS and viable cells 
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were counted (viability was assessed by alamarBlue Cell™ Viability Reagent (ThermoFisher 
Scientific).   
  
Luciferase assay 
SJPDGF1 cells (1×105) were infected with rAd-∆β4-luc at different MOIs. At indicated time points, 
luciferase was assessed by Steady-Glo® Luciferase Assay System (Promega). 
Statistics 
Mantel-Cox Log-Rank test was used to analyze Kaplan-Meier survival curves. Student’s T tests were 
used for in vitro and ex vivo analysis where appropriate. Statistical significance was determined at P < 
0.05. All analysis was performed using GraphPad Prism 8 software. 
 
 
RESULTS  
Restricting Ad-CD40L to tumor cells induces rejection without toxicity. 
To test the hypothesis that ligation of the CD40/CD40L axis would promote brainstem tumor
clearance with manageable toxicity, we used the GL261/C57BL/6 immunocompetent models of 
tumor growth in the brainstem. Although not derived from pediatric Diffuse Midline Gliomas, we 
have shown that GL261 can be reproducibly grown as transplantable tumors in the pons in the 
anatomic location that mirrors Diffuse Midline Glioma growth in patients5.  
Infection of GL261 cells with replication defective Ad-GFP or Ad-CD40L at various MOIs 
(0.1-10) did not induce direct cytotoxicity, but transgene expression was detected by 48h post-
infection (Figs. 1A&B). To determine the efficacy of CD40L as a mediator of immune rej ction in 
the brainstem, GL261 cells were pre-infected with Ad-GFP or Ad-CD40L immediately prior to 
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implantation into the brainstem using established coordinates17. Implantation of tumor cells pre-
infected with Ad-GFP (MOI 10) did not prolong survival of mice relative o mice treated with PBS 
(Fig. 1C). However, mice implanted with GL261 cells pre-infected with Ad-CD40L at MOI of 1 r
10 (but not 0.1) rejected tumors completely with no overt toxicity (Fig. 1C). To determine whether 
surviving mice developed long-term immunologic memory, they were re-challenged with the same 
tumor cells in the frontal lobe. While naïve mice succumbed to tumor by day 40, all mice wh ch 
survived the brainstem challenge rejected the frontal lobe re-challenge (Fi . 1D). These results 
suggest that highly targeted delivery of Ad-CD40L to tumors in the brainstem might i prove survival 
with manageable toxicity and represents a valuable model to explore further as a novel 
immunotherapy of Diffuse Midline Glioma.  
Ad-CD40L induces recruitment of immune cells into the tumor microenvironment. 
To characterize the mechanisms by which Ad-CD40L induced anti-tumor responses in the brainst m, 
we analyzed the induction of brain-infiltrating leukocytes (BILs) 8 days following implantation of 
tumor cells pre-infected with PBS, Ad-GFP, or Ad-CD40L (MOI 1). Treatment with Ad-CD40L 
induced a profound infiltration of CD45+ cells (Fig. 2A), largely composed of CD4+ and CD8+ T cells, 
CD19+ (B) cells, and NK cells (Fig. 2B). Ad-CD40L induced CD11b+Gr1+ cell infiltration (Fig. 2C) 
and importantly activated Class II and CD86 expression in CD11c+ and CD45midCD11b+ cells (Figs. 
2D&E). As shown by BrdU labeling, Ad-CD40L significantly promoted local proliferation of 
activated (CD44+) CD4+ T, CD8+ T, and CD19+ (B) cells (Fig. 2F).  In separate studies, we have also 
observed significant proliferation of adoptively transferred tumor specific T cells in the draining 
lymph nodes following intra-tumoral expression of CD40L.     
  In addition, Ad-CD40L induced recruitment of CXCR5+CD4+ T and B cells (Fig. 2G). 
Consistent with the CXCR5 receptor binding to CXCL13, a chemokine important in the generation of 
secondary/tertiary lymphoid structures (TLS), these CD4+ T cells expressed PD1 and ICOS which are 
markers of follicular CD4+ T cells (Fig. 2H). Similarly, CD4+ T cells and B220+ B cells clustered 
around the meninges following Ad-CD40L treatment, reminiscent of TLS formation (F g. 2I).  
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CD4+ T cells are critical for Ad-CD40L therapy 
To identify critical cellular types for therapy, we performed multiple antibody-mediated depletions of 
CD4+ T, CD8+ T, or B cells.  Of these, only depletion of CD4+ T cell significantly diminished the total 
number of BILs (Fig. 3A), under conditions which we confirmed led to depletions of CD4+ T, CD8+ 
T, or B cells (Fig. 3B). Depletion of B cells did not alter the number of CD4+ or CD8+ T cells. 
However, CD4 depletion reduced the number of CD19+CD40+ and CD19+II+ cells (Fig. 3C) and 
CD11c+CD40+, CD11c+II+, CD11b+F4/80+, or CD11b+Gr1+ cell numbers were all significantly 
decreased (Figs. 3D&E). CD4 depletion also suppressed microglia activation as evidenced by levels 
of CD45midCD11b+CD86+ and CD45midCD11b+II+ cells (Fig. 3F).  
Despite the fact that Ad-CD40L therapy recruited both CD8+ T cells and B cells, depletion of 
neither CD8+ T nor B cells significantly altered survival compared to the IgG control. In contrast, 
CD4+ cell depletion drastically reduced Ad-CD40L therapy, showing CD4+ T cells were absolutely 
and obligatorily required for therapy (Fig. 3G). Regardless of whether mice survived following 
depletion of either CD8+ T or B cells, all of these surviving mice developed long-term anti-tumor 
memory responses against a re-challenge with GL261 cells in the frontal lobe (Fig. 3H).  In addition 
to providing helper function to generate intrinsic antitumor immune responses, CD4+ T cell have also 
been reported to have direct cytotoxicity against tumor cells20,21.  In this respect, CD4+ T cells isolated 
from spleens of mice treated with Ad-CD40L significantly inhibited the prolife ation of target GL261 
cells in vitro compared to CD4+ T cells from untreated mice, or from mice treated with Ad-GFP (Fig. 
3I).  This inhibition of tumor cell proliferation may be contributed by some dirct cytotoxicity and/or 
through a directly cytostatic effect exerted by the CD4+ T cells.  This anti-proliferative activity on 
GL261 targets was also associated with low, but detectable levels of IFN- secretion by the CD4+ T 
cells from Ad-CD40L-treated mice.  In contrast, neither inhibition of proliferation against GL261 
cells, nor IFN- secretion, was observed from CD4+ T cells from mice treated with PBS or Ad-GFP 
(Fig. 3J).   
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CD4+ T cell mediated anti-proliferative effects against GL261 targets in vitro absolutely required pre-
treatment of GL261 cells with IFN-.  Although MHC Class II expression was undetectable on GL261 
cells growing in vitro, pre-treatment for 24hrs with IFN- induced relatively high levels 
(Supplementary Fig. S1A).  Consistent with GL261 tumors being the target of direct CD4+ T cell-
mediated inhibition of proliferation following Ad-CD40L treatment, GL261 tumors excised from the 
brainstems of mice treated with PBS had highly significantly lower levels of MHC Class II expression 
than did GL261 tumors from brainstems of mice treated with Ad-CD40L (Supplementary Fig. S1B).  
In addition, GL261 tumors showed significant induction of IFN- in Ad-CD40L-treated tumors 
compared to PBS or Ad-GFP-treated tumors (Supplementary Fig. S1C) which is consistent with 
induction of MHC Class II presented targets on tumors for CD4+ T cell mediated recognition. We 
have not tested tumors directly from patients for MHC Class II expression.  However, although 
neither of the two DMG cell lines SJPDGF1 and SF7761 express detectable MHC Class II molecules 
in normal cell culture, pre-treatment for 24hrs with huma  IFN- did induce Class II expression (200 
fold, SJPDGF1 and 1000 fold, SF7761).  So, although we do not know if patient tumors in situ 
express Class II, patient-derived lines, cultured for multiple passages in vitro, have the capacity to do 
so.   
  Taken together, these data are consistent with a model in which Ad-CD40L induces a 
population of CD4+ T cells which exerts anti-proliferative effects on GL261 tumors growing in situ, in 
part through an in vivo upregulation of MHC Class II on the tumor cells as a result of the pro-
inflammatory tumor micro-environment induced by Ad-CD40L.  
Therefore, CD4+ T cells were necessary to activate antigen-presenting cells, B cells and 
microglia, and were critical mediators of Ad-CD40L therapy – at least in part through a highly anti-
proliferative activity against tumor cells.  
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Intra-tumoral injection of Ad-CD40L improves survival of glioma-bearing mice. 
Next, we assessed efficacy and toxicity of Ad-CD40L in an intra-tumoral injection model of 
established brainstem tumors.  Direct injection of Ad-GFP at 106 pfu did not prolong survival of mice, 
all of which died of tumor growth (Fig. 4A). When mice were treated with 106 pfu of Ad-CD40L, 
significant acute toxicity was observed, with loss of up to 20% body weight (Fig. 4B) and some 
deaths (Fig. 4A) within the first 30 days post treatment.  However, with supportive care (fluid 
treatment) about 40% of these mice recovered and survived long term (Figs. 4A&B). Treatment with 
Ad-CD40L was dose dependent as neither 5×104, nor 105 pfu, significantly extended survival through 
tumor treatment (Fig. 4A) but neither did they induce high level toxicity (Fig. 4B). Significant 
numbers of long term tumor cures could be induced by increasing the dose of Ad-CD40L as high as 
5×106 or 107 pfu, compared to mice treated with Ad-GFP at 107 pfu (Fig. 4C), provided fluids and 
nutrient support were provided over a period of two weeks (Fig. 4D).  
RNA-seq transcriptional profiling 8 days post-injection of tumor-bearing mice treated with PBS, Ad-
GFP, or Ad-CD40L using Ingenuity Pathway Analysis (IPA; 
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/) showed that Ad-
CD40L induced genes involved in signaling pathways of neuroinflammation, T and B cell signa ing, 
Th1 and Th2 activation, communication between innate and adaptive immune cells, and DC 
maturation (Fig. 4E). Among genes which were most differentially expressed in each pathway 
(log2FC 3), IL-1 , IL-6, IFN- , TNF-α, CD40, IL1β- , and TLRβ were shared between each of the 
top 5 pathways (Fig. 4F).  Consistent with Fig. 2, genes responsible for B and T cell recruitment were 
also strongly up-regulated in Ad-CD40L treatment. Thus, Ad-CD40L activated proinflammatory 
cytokines/chemokines, which are candidates as mediators of efficacy, toxicity r both.  Consistent 
with the ability of Ad-CD40L to reverse the immune suppressive tumor micro-environment, treatment 
with Ad-CD40L induced both significant reductions in the expression of immune s ppressive factors, 
such as TGF-  and FOX-P3, as well as increased expression of other cytokines including IFN- and 
IL -6, compared to PBS or Ad-GFP treatment (Supplementary Fig. S1)  
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Ad-CD40L therapy is associated with tertiary lymphoid structure-like formation.  
Brains of tumor-bearing mice 9d post treatment showed reproducibly smaller, or absence of, tumors 
following treatment with Ad-CD40L (Fig. 5A, left panel) along with consistently higher levels of 
CD4+ T cells (Fig. 5A, middle panel). B and CD3+ T cell were present along the meninges of Ad-
CD40L-treated brains, organized in a manner that resembled TLS as found in inflamed or tumoral 
tissue22 (Fig. 5A, right panel). In this respect, levels of Claudin-5, a marker of vessel formation in the 
brain23, were significantly upregulated following Ad-CD40L treatment compared to PBS or Ad-GFP 
(Supplementary Fig. S1G) The formation of these TLS and increased vascularization are compatible 
with a wound-healing type response to the inflammatory effects of Ad-CD40L.  Brains harvested on 
days 2, 3, and 8 post-infection showed significantly increased numbers of CD45+ BILs following 
treatment with Ad-CD40L compared to Ad-GFP, as early as 72 hours post-infection (Fig. 5B). Ad-
CD40L also significantly increased CD11b+CD11c+, CD11b+Gr1+, CD11c+II+, 
CD45midCD11b+CD40+, and CD45midCD11b+II+ cells (Supplementary Fig. S2). Similar to the pre-
infection model, the majority of total cells in Ad-CD40L-treated mice were CD4+ T, CD8+ T, and B 
cells (Figs. 5C-E). Interestingly, when Ad-CD40L was intra-cranially injected without tumor present, 
total BILs or CD45+ cells were not significantly different in mice injected with Ad-GFP or Ad-
CD40L (Supplementary Figs. S3A&B). Notably, we detected a marginal enhancement in CD8+ T 
and B cells (Supplementary Figs. S3D&E), whereas CD4+ T and NK cells were decreased in Ad-
CD40L-treated tumor-free animals (Supplementary Figs. S3C&F). Therefore, the specific profile of 
immune cells depends on the presence of tumors in the brain. 
Sera from tumor-bearing mice treated with Ad-CD40L significantly increased IgG levels 
specifically against GL261, but not against normal brain-derived mixed astrocyte cells24 as a negative 
control (Fig. 5F), showing that Ad-CD40L induces both adaptive and humoral anti-tumor immune 
responses.  However, the role of these tumor-specific antibodies remains unclear since depletion of B 
cells had no significant effects on therapy (Fig. 3G).  
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Finally, consistent with the results of Figure 3G with the pre-transduced model, depletion of 
CD4+ T cells completely abolished in vivo therapy following direct delivery of Ad-CD40L virus to 
established tumors (Fig. 5G).  In this model, however, depletion of CD8+ T cells also reduced 
therapeutic efficacy compared to CD8+ intact mice, suggesting that effector CD8+ T cell responses 
may also play a role in therapy of direct virus delivery (Fig. 5G). 
 
Replication competent adenovirus expressing CD40L improves anti-tumor efficacy while 
minimizing off tumor toxicity. 
We hypothesized that off-target expression of Ad-CD40L in non-tumor brain tissue led to 
proinflammatory cytokine/chemokine production and the acute toxicity of Fig.4. Therefore, for 
clinical translation of CD40L therapy for Diffuse Midline Gliomas it will be important to restrict 
CD40L expression to tumor cells in vivo.  To achieve this goal, we exploited the tumor specific 
targeting conferred upon the replication competency of adenoviruses afforded by the incorporation of 
a 24-bp deletion in the E1A viral gene (rAd-Δβ4) responsible for pRB protein binding25. Since many 
gliomas, including Diffuse Midline Gliomas, have defects in the p16/Rb/E2F pathway26,27, the 24-bp 
deletion in the E1A gene confers rAd-Δβ4 with high levels of selectivity to glioma cells. Therefore, 
we constructed rAd-Δβ4-CD40L in which expression of CD40L will ultimately be under the control 
of the highly tumor selective replication of the virus.   
To validate the replication and anti-tumor efficacy of this virus in human tumors, the patient-
derived Diffuse Midline Glioma cell line SJPDGF1 was infected with rAd-Δβ4 expressing luciferase 
(rAd-Δβ4-luc). Virus infection and transgene expression was observed within 3 days, which decreased 
with time due to the cytotoxicity associated with replication and oncolysis (Fig. 6A). Consistent with 
this, rAd-Δβ4-luc and rAd-Δβ4-CD40L killed almost 60 % of SJPDGF1 cells by day 6 (Fig. 6B), 
results which were reproduced in a second human patient-derived Diffuse Midline Glioma cell line 
SF7761 (Fig. 6B).  
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Assessing the activity of rAd-Δβ4-CD40L in patient-derived xenografts would require 
immunocompromised mice, thereby eliminating the immune-mediated effects of CD40L expression.  
Therefore, we tested the anti-tumor efficacy of rAd-Δβ4-CD40L in two different murine immune 
competent models where either GL261 or CT2A cells were implanted into the brainstem on day 0, 
and rAd-Δβ4s were intra-tumorally injected on day 10.  Whilst these murine cells only partially 
support adenoviral replication, they represent the effects of intact immune subsets on both anti-tumor 
efficacy and toxicity. rAd-Δβ4-CD40L significantly improved survival of tumor-bearing mice over 
PBS, or rAd-Δβ4-luc, in both immune-competent GL261 and CT2A scenarios, and led to at least 50% 
cure rates in these aggressive models (Figs. 6C&E). Most importantly, rAd-Δβ4-CD40L did not 
induce weight loss to the same degree as replication defective Ad-CD40L (Fig. 4). GL261-bearing 
mice treated with rAd-Δβ4-CD40L lost less than 25% body weight 2 days post-infection, and 
recovered within 14 days (Fig. 6D). Similarly, CT2A-bearing mice treated with rAd-Δβ4-CD40L had 
weight loss less than 20% (Fig. 6F).   
To investigate the relative toxicity of the rAd-Δβ4-CD40L virus to tumor and normal brain 
tissue, mixed astrocyte/glial cultures from normal brains of C57Bl/6 mice wer infected with 
increasing MOI of the rAd-Δβ4-CD40L virus.  Despite the relatively poor ability of replication 
competent adenoviruses to replicate in murine cells, both CT2A and GL261 glioma cell lines showed 
significant cytotoxicity upon infection with rAd-Δβ4-CD40L (Supplementary Fig. S4), consistent 
with the cytotoxicity observed against human Diffuse Midline Glioma cell lines (Fig. 6B).  In 
contrast, similar MOI of rAd-Δβ4-CD40L used to infect normal astrocyte/glial cultures did not cause 
significant reduction in cell numbers compared to mock infection (Supplementary Fig. S4). These 
data confirm that the Δβ4 mutation confers a tight degree of targeting of virus replication upon 
transformed glioma cell types, as opposed to normal brain cells. 
Our data in Fig. 4 demonstrated that both IL-6 and IL-1  were up-regulated in Ad-CD40L 
treated tumors which were associated with high levels of toxicity.  Therefor , we hypothesized that 
blocking these cytokines during therapy would reduce the toxicity associated with CD40L treatment 
whilst not necessarily diminishing therapy.  In this respect, blockade of IL-6 and IL-1  using 
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neutralizing antibodies – a strategy which is directly translatable to clinical studies28 – allowed us to 
escalate the intra-tumoral treatment dose of rAd-Δβ4 CD40L as high as 107 pfu in the GL261 model 
with manageable and non-toxic levels of body weight loss  (Fig. 6D). Treatment with neither anti-IL -
6, anti-IL -1  or a combination of the two, had any effect on therapy of GL261 tumors.  Consistent 
with these results, histopathologic studies of the mouse brains on day 20 post-injection d monstrated 
that rAd-Δβ4-CD40L treated mice exhibited smaller tumors than control mice (Figs. 6G&H).  
 
Discussion  
New, aggressive therapies for Diffuse Midline Gliomas and other pediatric brainstem tumors 
are urgently required. CD40/CD40L engagement has generated potent anti-tumor responses in 
multiple preclinical models in anatomic locations where high levels of inflammation can be readily 
tolerated6,7. Therefore, in this study, we sought to address two major questions.  First, we 
hypothesized that direct delivery of adenovirus expressing CD40L (Ad-CD40L) to brainstem tumors 
would induce immune mediated anti-tumor clearance.  Second, we tested whether such therapy would 
be associated with manageable toxicity due to immune-mediated inflammation in the brainstem. 
To investigate the twin components of immune-mediated efficacy and toxicity of the Ad-
CD40L strategy, immune competent pre-clinical models are essential.  Unfortunately, we were unable 
to grow explanted cell lines derived from the RCAS spontaneous model of Diffuse Midline Glioma29 
reproducibly in our mice.  Therefore, for the current studies, we used GL261 and CT2A murine 
gliomas.   Although these lines are not derived from Diffuse Midline Gliomas, we have shown that 
they can be reproducibly grown as transplantable tumors in the pons in the ana omic location that 
mirrors Diffuse Midline Glioma growth in patients5.  Therefore, although the models of therapy and 
delivery that we have used here are not perfect replicates of the human situation, we believ  that 
CD40L-mediated treatment of these realistically located tumors will reflect the efficacy and, 
importantly, the immune mediated toxicity associated with immunotherapy for Diffuse Midline 
Gliomas.   
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Although Ad-CD40L did not induce a direct cytopathic effect (Fig. 1A), pre-infection of tumor cells 
before implantation into the brainstem induced complete tumor rejection and long-lasti  anti-tumor 
memory without overt toxicity (Figs. 1C&D).  Our data show that CD4+ T cells were absolutely 
required for Ad-CD40L therapy, as depletion of these cells abolished APC activation and abrogated 
tumor rejection (Fig. 3G).  The data of Figures 3I&J show that, consistent with other reports of the 
therapeutic role of anti-tumor cytotoxic CD4+ T cells20,21,  this dependence upon CD4+ T cells for anti-
tumor therapy is, at least in part, due to the generation of CD4+ T cells which exert a direct anti-
proliferative effect upon target tumor cells.  Central to this mechanism of actin is the conversion of 
the tumor micro-environment from an immune quiescent phenotype to an immune inflamed 
phenotype which allows for up-regulation of MHC Class II molecules on the target tumor 
(Supplementary Figs. S1A-C).   Moreover, the cumulative data of Figs. 2&3 suggest that CD40L-
activated CD4+ T cells were central in maintaining and licensing APCs to relay CD4+ T cell help to 
CTLs which have at least some role in directly delivered anti-tumor therapy (Fig. 5G).  These data are 
consistent with reports showing that the interaction of CD40/CD40L on APCs and activated CD4+ T 
cells promotes priming of potent anti-tumor T cells6,30,31 and helps to maintain neuroprotection 
through MHCII+ APCs32.  In addition, we observed structures reminiscent of TLS around the 
meninges near the tumor areas in mice treated with Ad-CD40L – structures which could be a positive 
prognostic factor33 acting as privil ged sites for local priming, activation, and proliferation of long-
lasting memory T helper, cytotoxic cells, memory B cells, and antibody-producing plasma cells34-36.  
It may, therefore, be that these lymphoid-like aggregates found in Ad-CD40L-treated brains are local 
sites of antigen presentation for B and T cell activation37.  However, further studies are required to 
understand the role of these structures and the generation of the anti-glioma immune responses in our 
model.  In addition, ongoing phenotyping studies of the effector CD4+ and CD8+ T cells induced by 
CD40L treatment suggest that additional combination with immune checkpoint blockade may add 
further therapeutic potential to this approach – although additional toxicities may also be induced.     
The interaction of follicular CD4+ T cells and B cells promotes B cell differentiation into 
antibody-secreting cells38.  In this respect, sera from tumor-bearing mice treated with Ad-CD40L 
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significantly increased IgG levels specifically against GL261, but not against normal brain-derived + 
astrocyte cells24. Although it is tempting to speculate that CD40L-induced anti-tumor antibody 
contributed to therapy, the depletion of B cells had no significant effects on tumor treatment and so 
the role of these antibodies remains to be elucidated (Fig. 3G). 
Our data from the pre-infection model showed that tumor-restricted expression of CD40L 
represents an excellent candidate to induce immune mediated rejection of tumor cells growing in the 
brainstem without necessarily inducing catastrophic toxicity.  However, direct elivery of Ad-CD40L 
to established tumors did induce acute toxicity before day 30.  Mice which survived that toxicity with 
fluid and nutrient support were cured of tumor (Figs.4A&C).  We believe that this toxicity was a 
result of viral infection of non-tumor tissue following direct injection, which did not occur with pre-
infection of tumor cells with the replication-defective Ad-CD40L. Consistent with this, intracranial 
injection of Ad-CD40L into mice without tumors induced neurological symptoms as early as 5 days 
post injection, almost certainly associated with CD40L expression in non-tumor brain tissue leading 
to proinflammatory cytokines/chemokines production and acute toxicity, as supported by our RNA-
seq transcriptional profile data (Fig. 4).  
Clinically, our ultimate goal will be to restrict CD40L expression to tumor cells in vivo.   
Therefore, we exploited the tumor specific targeting conferred upon the replication ompetency of 
adenoviruses afforded by the incorporation of a 24-bp deletion in the E1A viral gene (rAd-Δβ4) 
responsible for pRB protein binding25.  The abnormalities of p16/Rb/E2F pathway allow oncolytic 
adenovirus with 24-bp deletion in E1A gene to preferentially replicate in gliomas26 which have 
disrupted Rb function, and confers anti-glioma responses25,39 .  Moreover, the backbone of this virus 
(without CD40L) has entered clinical trials for Diffuse Midline Glioma39. As expected of these tumor-
specific, replication competent, oncolytic viruses, both the control rAd-Δβ4-luc and the rAd-Δβ4-
CD40L viruses were cytolytic for patient-derived Diffuse Midline Glioma celllines, SJPDGF1 and 
SF7761.  Therefore, although it would be possible to assess the direct oncolytic activity of rAd-Δβ4-
CD40L in patient-derived xenografts, these experiments would have to be performed in immu e 
deficient mice and both viruses would likely achieve similar anti-tumor effects.  However, tumor 
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therapy experiments in immune deficient mice would not reflect the immune-mediated effects of 
CD40L expression.  Therefore, to assess the combined oncolytic and immunotherapeutic effect of
CD40L expressed from the virus, we tested the anti-tumor efficacy of rAd-Δβ4-CD40L in two 
different murine immune competent models (GL261 and CT2A).  Whilst these murine cells only 
partially support adenoviral replication, they do reflect the effects of intact immune subsets on both 
anti-tumor efficacy and toxicity. Importantly, the rAd-Δβ4-luc virus could not prolong the survival of 
brainstem tumor-bearing mice (Fig. 6). In contrast, incorporation of CD40L into the E1A mutant Δβ4 
adenovirus, resulted in long term cures of 50%-70% of GL261 or CT2A brainstem tumor-bearing 
mice (Fig. 6). Because of the very limited replication of adenoviruses in these murine cells, our results 
here likely underestimate the levels of CD40L transgene spread and expression (and potentially 
therapy) that could be achieved in a human tumor where replication is more efficient.  Importantly, 
however, the inclusion of the transgene into this vector whose replication is restricted to tumor cells 
greatly ameliorated the toxicity that we had observed with the Ad-CD40L vector, and this could be 
entirely rescued by nutrient and fluid support.  We used RNA-seq transcriptional profiling analysis 
(Fig. 4) to improve the safety profile still further.  These data showed that IL -6 and IL-1  were 
consistently amongst the most differentially expressed cytokines between all five pathways 
upregulated by CD40L treatment of brainstem tumors (Fig. 4F).  Since antibody neutralization of 
both of these cytokines is clinically useful in other scenarios28, we hypothesized that blocking these 
cytokines during therapy would reduce the toxicity associated with CD40L treatment.  Consistent 
with this, blockade of IL-6 and IL-1  allowed us to escalate the intra-tumoral treatment dose of rAd-
Δβ4-CD40L as high as 107 pfu in the GL261 model with manageable and non-toxic levels of body 
weight loss (Figs. 6D, G&H).       
In conclusion, we show here that CD40L expressed from an adenoviral platform can 
potentially reverse the immunosuppressive environment in glioblastoma by recruiting and maintaining 
innate and adaptive anti-tumor immune responses in the brainstem.  This is the first repo t, to our 
knowledge, showing that CD4+ T cells play a critical role in Ad-CD40L therapy for brainstem tumors. 
We also show that the tumor restricted, replication competent rAd-Δβ4-CD40L has cytotoxicity 
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against human patient-derived Diffuse Midline Glioma cell lines in vitro, generates tumor cures 
against orthotopic brainstem gliomas in two different, fully immune competent, murine models and 
can be used in combination with cytokine neutralization at high intra-tumoral titers with readily 
manageable toxicity.  Therefore, we believe that, by building on the rAd-Δβ4 backbone which is 
already in clinical trials for Diffuse Midline Glioma39, rAd-Δβ4-CD40L represents a promising 
therapeutic for clinical evaluation as a treatment of brainstem tumors in the context of direct intra-
tumoral injection with careful dose escalation. 
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Figure legends  
Fig. 1. Restricted expression of CD40L in tumor cells exerts anti-tumor response. (A) GL261 
cells were infected with different MOIs of Ad-GFP or Ad-CD40L, and cell viability was measured 
using MTT assay. Error bars ± SD. (B) GL261 cells were infected with Ad-GFP (MOI 1) and GFP 
expression was detected using florescence microscopy (20X). Scale bar, 100 µm. (C) Survival curves 
of mice treated with GL261 cells pre-infected with viruses and implanted into the brainstem (d0). (D) 
Survival curves of mice which survived in (C) and were re-challenged with parental GL261 in the 
frontal lobe. *P≤0.05, ** P≤0.01 
 
Fig. 2. Ad-CD40L induces immune cell infiltration in brain tumors. Mice were implanted with 
GL261 tumors pre-infected with PBS, Ad-GFP, or Ad-CD40L (MOI 1) on day 0. Mice were given 
BrdU on day 7, and brains were perfused and harvested on day 8 for flow analysis. Numbers of total 
(A) CD45+ (B) CD4+ T, CD8+ T, CD19+, NK1.1+ (C) CD11b+Gr1+ (D) CD11c+II+ (E) CD45midCD11b+ 
(F) CD44+BrdU+ (G) CXCR5+ (H) CD4+PD1+ICOS+. Error bars ± SD (n=4). Student’s t-test: 
*P≤0.05, ** P≤0.01, *** P≤0.001, **** P≤0.0001. (I) Representative images (40X) of brains day 8 
post-implantation stained with dapi, B220, and CD4. Scale bar, 50 µm. 
 
Fig. 3. CD4 depletion abrogates Ad-CD40L therapy. Immune cells were depleted 3 days before 
implanting pre-infected cells. Brains were harvested on day 8. Number of total (A) BILs (B) CD45+ 
(C) CD19+ (D) CD11c+ (E) CD11b+ (F) CD45midCD11b+ cells. Error bars ± SD (n=γ). Student’s t-test: 
*P≤0.05, ** P≤0.01. (G) Survival curves of immune cell-depleted mice implanted with pre-infected 
GLβ61 cells. ** P≤0.01. (H) Survival curves of re-challenge of surviving mice from (G). All 
treatments ** P≤0.01 over naïve control.  (I,J)  Mice with 10 day established GL261 tumors were 
injected with PBS or with 5x106 pfu of Ad-GFP or Ad-CD40L.  5 days later, CD4+ T cells were 
purified from splenocytes by magnetic bead separation.  CD4+ T cells pooled from three mice per 
treatment group were co-cultured with 104 GL261 target cells pre-treated for 24hr with murine IFN- 
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(20U/ml) at an Effector:Target ratio of 10:1 (triplicate wells).  The number of surviving GL261 cells 
48hrs later is shown (I) for GL261 cells co-cultured with: 1: no CD4+ T cells; 2: CD4+ T cells from 
naïve mice (no tumor, no treatment); 3: CD4+ T cells from tumor bearing mice treated with PBS; 4: 
CD4+ T cells from tumor bearing mice treated with Ad-GFP; 5: CD4+ T cells from tumor bearing 
mice treated with Ad-CD40L.  J. Supernatants harvested from these cultures were assayed for levels 
of IFN- by ELISA.     
 
Fig. 4. Intra-tumoral injection of Ad-CD40L results in tumor clearance with acute toxicity. 
(A&C) Survival curves of tumor-bearing mice treated with viruses. (B&D) Percent body weight loss 
of GL261-bearing mice treated with Ad-CD40L. Tumor bearing mice were intra-tumorally injected 
with viruses. On day 8, total RNA was isolated for RNA-seq analysis. (E) Top 12 canonical pathways 
compared between Ad-GFP and Ad-CD40L. (F) Heat map of genes expressed in Ad-GFP or Ad-
CD40L over PBS (Expression log ratio ≥γ) in top 5 canonical pathways.  
 
Fig. 5. Intra-tumoral injection of Ad-CD40L induces immune cell infiltration and anti-tumor 
antibody. (A) Representative images (40X) of tumor-bearing mice treated with viruses. Left panel, 
H&E staining; middle panel (arrow), brain tissues stained with dapi, B220, and CD4 (scale bar, 100 
µm); right panel (inset), brain tissues stained with dapi, B220, and CD3 (scale bar, 50 µm). (B-F) 
Flow analysis of brains treated with PBS, Ad-GFP, or Ad-CD40L. Numbers of total (B) CD45+ (C) 
CD4+ T (D) CD8+ T (E) CD19+ cells. Error bars ± SD (n=γ). Student’s t-test; *P≤0.05, ** P≤0.01, 
**** P≤0.0001. (F) Average of median fluorescent intensity of IgG levels.  Error bars ± SD (n=3). 
Student’s; *P≤0.05, ** P≤0.01.  (G) Mice injected with GL261 brainstem tumors on day 1 were 
injected with control IgG or with depleting antibodies against CD4+T, CD8+T or NK cells on days 6, 
8, 10 &12.  Mice (n=6) were injected intra-tumorally with PBS or with 1x106 pfu of Ad-CD40L on 
day 10.  Survival with time is shown.  
 
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/n
e
u
ro
-o
n
c
o
lo
g
y
/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/n
e
u
o
n
c
/n
o
a
a
1
2
6
/5
8
4
7
7
5
2
 b
y
 C
a
rd
iff U
n
iv
e
rs
ity
 u
s
e
r o
n
 2
8
 M
a
y
 2
0
2
0
Ac
ce
pte
d M
an
us
cri
pt
29 
 
Fig. 6. rAd-Δ24-CD40L treats brainstem tumors. (A) SJPDGF1 cells were infected with rAd-Δ24-
luc at different MOIs and luciferase activity measured. (B) SJPDGF1 or SF7761 cells were infected 
with rAd-Δ24-luc or rAd-Δ24-CD40L and cell viability assessed by MTT assay. (C) Survival curves 
of GL261 tumor-bearing mice injected with PBS, rAd-Δ24-luc or rAd-Δ24-CD40L +/- anti-IL -6 and 
anti-IL -1  neutralizing antibodies. *P≤0.05, ** P≤0.01. (D) Percent body weight loss of GL261-
bearing mice treated with rAd-Δ24s. (E) Survival curves of CT2A tumor-bearing mice injected with 
PBS, rAd-Δ24-luc or rAd-Δ24-CD40L. ** P≤0.01. (F) Percent body weight loss of CT2A-bearing 
mice treated with rAd-Δ24s. (G) Representative images of H&E staining. (H) Tumor area of GL261-
bearing mice treated with rAd-Δ24s. Error bars ± SD (n=3). 
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